p53 mutants without a functional tetramerisation domain are not oncogenic

Journal of Molecular Biology

Volumn 286, Issue 5, 1999, Pages 1269-1274

  Chène, Patrick ^a   Bechter, Elisabeth ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dominant negative effect; Gain of function; p53; Tetramerisation

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; MUTANT PROTEIN; PROTEIN P53; TETRAMER;

ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; MISSENSE MUTATION; OLIGOMERIZATION; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; REPORTER GENE; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

EID: 0344267643     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.2563     Document Type: Article

References (27)

1. Albor A., Kaku S., Kulesz-Martin M. Wild-type and mutants forms of p53 activate human topoisomerase I: a possible mechanism for gain of function. Cancer Res. 58:1998;2091-2094.
2. Cariello N. F., Douglas G. R., Soussi T. Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents. Nucl. Acids Res. 24:1996;119-120.
3. Chène P. In vitro analysis of the dominant negative effect of p53 mutants. J. Mol. Biol. 281:1998;205-209.
4. Chéne P., Mittl P., Grütter M. In vitro structure-function analysis of the β-strand 326-333 of human p53. J. Mol. Biol. 273:1997;873-881.
5. Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 255:1992;459-462.
6. Davison T. S., Yin P., Nie E., Kay C., Arrowsmith C. H. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene. 17:1998;651-656.
7. Dittmer D., Pati S., Zarnbetti G., Chu S., Teresky A. K., Moore M., Finlay C., Levine A. J. Gain of function mutations in p53. Nature Genet. 4:1993;42-46.
8. Donehower L. A., Bradley A. The tumor suppressor p53. Biochim. Biophys. Acta. 1155:1993;181-205.
9. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. Wafl, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
10. Forrester K., Lupold S. E., Ott V. L., Chay C. H., Band V., Wang X. W., Harris C. C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene. 10:1995;2103-2111.
11. Frazier M. W., He X., Wang J., Gu Z., Cleveland J. L., Zambetti G. P. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol. Cell. Biol. 18:1998;3735-3743.
12. Gualberto A., Aldape K., Kozakiewicz K., Tlsty T. D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl Acad. Sci. USA. 95:1998;5166-5171.
13. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 253:1991;49-53.
14. Iwamoto K. S., Mizuno T., Ito T., Tsuyama N., Kyoizumi S., Seyama T. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res. 56:1996;3862-3865.
15. Ko L. J., Prives C. P53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
16. Lányi A., Deb D., Seymour R. C., Ludes-Meyers J. H., Subler M. A., Deb S. 'Gain of function' phenotype of tumor-derived mutant p53 derives the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene. 16:1998;3169-3176.
17. Levine A. J., Wu M. C., Chang A., Silver A., Attiyeh E. F., Lin J., Epstein C. B. The spectrum of mutations at the p53 locus. Ann. NY Acad. Sci. 768:1995;111-128.
18. Lin J., Teresky A. K., Levine A. J. Two critical hydrophobic amino acids in the N-terminal domain of p53 protein are required for the gain of function phenotype of human p53 mutants. Oncogene. 10:1995;2387-2390.
19. Lomax M. E., Barnes D. M., Hupp T. R., Picksley S. M., Camplejohn R. S. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene. 17:1998;643-649.
20. Milner J., Medcalf E. A. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 into the mutant conformation. Cell. 65:1991;765-774.
21. Rollenhagen C., Chène P. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain. Int. J. Cancer. 78:1998;372-376.
22. Shaulian E., Zauberman A., Ginsberg D., Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:1992;5581-5592.
23. Strauss B. E., Haas M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant p53 proteins. Biochim. Biophys. Res. Commun. 217:1995;333-340.
24. Thottassery J. V., Zambetti G. P., Arimori K., Schuetz E. G., Schuetz J. D. P53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA. 94:1997;11037-11042.
25. Varley J. M., McGown G., Thorncroft M., Cochrane S., Morrison P., Woll P., Kelsey A. M., Mitchell E. L. D., Boyle J., Birch J. M., Evans D. G. R. A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni sydrome. Oncogene. 12:1996;2437-2442.
26. Waterman J. L. F., Shenk J. L., Halazonetis T. D. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14:1995;512-519.
27. Zastawny R. L., Salvino R., Chen J., Benchimol S., Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene. 8:1993;1529-1535.